{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T20:38:18Z","timestamp":1719952698376},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.ejphar.2016.07.004","type":"journal-article","created":{"date-parts":[[2016,7,6]],"date-time":"2016-07-06T00:36:39Z","timestamp":1467765399000},"page":"68-74","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Influence of sub-chronic selective 11\u03b2-hydroxysteroid dehydrogenase 1 inhibition on the hypothalamic-pituitary-adrenal axis in female cynomolgus monkeys"],"prefix":"10.1016","volume":"789","author":[{"given":"Bradford S.","family":"Hamilton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinna","family":"Schoelch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Schuler-Metz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Krosky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak S.","family":"Lala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Claremon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard M.","family":"McGeehan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2016.07.004_bib1","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/sj.ijo.0803677","article-title":"Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects","volume":"31","author":"Alberti","year":"2007","journal-title":"Int. J. Obes. (Lond.)"},{"key":"10.1016\/j.ejphar.2016.07.004_bib2","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s40265-013-0112-5","article-title":"11beta-HSD1 inhibitors for the treatment of type 2 diabetes and cardiovascular disease","volume":"73","author":"Anderson","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2016.07.004_bib3","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1210\/jc.2007-1912","article-title":"Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor","volume":"93","author":"Courtney","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2016.07.004_bib4","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/oby.2006.92","article-title":"11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients","volume":"14","author":"Desbriere","year":"2006","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.ejphar.2016.07.004_bib5","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1463-1326.2011.01375.x","article-title":"Effects of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome","volume":"13","author":"Feig","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejphar.2016.07.004_bib6","first-page":"E348","article-title":"Levels of plasma C19 steroids and 5 alpha-reduced C19 steroid glucuronides in primates, rodents, and domestic animals","volume":"271","author":"Guillemette","year":"1996","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejphar.2016.07.004_bib7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejphar.2014.10.053","article-title":"Pharmacological characterization of the selective 11beta-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes","volume":"746","author":"Hamilton","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2016.07.004_bib8","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.tem.2010.06.004","article-title":"Will treating diabetes with 11beta-HSD1 inhibitors affect the HPA axis?","volume":"21","author":"Harno","year":"2010","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2016.07.004_bib9","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1126\/science.1066285","article-title":"A transgenic model of visceral obesity and the metabolic syndrome","volume":"294","author":"Masuzaki","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2016.07.004_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1172\/JCI17845","article-title":"Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice","volume":"112","author":"Masuzaki","year":"2003","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.ejphar.2016.07.004_bib11","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/oby.2007.618","article-title":"Omental 11beta-hydroxysteroid dehydrogenase 1 correlates with fat cell size independently of obesity","volume":"15","author":"Michailidou","year":"2007","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.ejphar.2016.07.004_bib12","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/diabetes.53.4.931","article-title":"Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice","volume":"53","author":"Morton","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2016.07.004_bib13","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s11695-008-9616-6","article-title":"11beta-hydroxysteroid dehydrogenase type 1 is overexpressed in subcutaneous adipose tissue of morbidly obese patients","volume":"19","author":"Munoz","year":"2009","journal-title":"Obes. Surg."},{"key":"10.1016\/j.ejphar.2016.07.004_bib14","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/oby.2007.233","article-title":"11Beta-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization","volume":"15","author":"Paulsen","year":"2007","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.ejphar.2016.07.004_bib15","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.2337\/dc09-2315","article-title":"The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy","volume":"33","author":"Rosenstock","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2016.07.004_bib16","first-page":"57","article-title":"Absence of Cushingoid phenotype in a patient with Cushing\u2019s disease due to defective cortisone to cortisol conversion","volume":"87","author":"Tomlinson","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2016.07.004_bib17","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.2337\/db08-0495","article-title":"Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity","volume":"57","author":"Tomlinson","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2016.07.004_bib18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1463-1326.2008.00911.x","article-title":"Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice","volume":"11","author":"Veniant","year":"2009","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejphar.2016.07.004_bib19","first-page":"3155","article-title":"Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation","volume":"80","author":"Walker","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2016.07.004_bib20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0889-8529(18)30102-6","article-title":"Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess","volume":"23","author":"Walker","year":"1994","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"10.1016\/j.ejphar.2016.07.004_bib21","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.drudis.2007.06.001","article-title":"Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target","volume":"12","author":"Wamil","year":"2007","journal-title":"Drug Discov. Today"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299916304344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299916304344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T15:26:09Z","timestamp":1568129169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299916304344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":21,"alternative-id":["S0014299916304344"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2016.07.004","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of sub-chronic selective 11\u03b2-hydroxysteroid dehydrogenase 1 inhibition on the hypothalamic-pituitary-adrenal axis in female cynomolgus monkeys","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2016.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}